BioMimetix JV

BioMimetix is a clinical-stage biotechnology company focused on developing a new class of antioxidant mimetics for oncology and other inflammatory conditions. The company's proprietary platform is based on manganese porphyrins, which function as potent mimics of the enzyme superoxide dismutase (SOD) to modulate cellular redox states. Its lead candidate, BMX-001, is currently in Phase 2 clinical trials designed to protect normal tissues from the damaging effects of radiation therapy while simultaneously enhancing the anti-tumor efficacy of the treatment. BioMimetix targets high-unmet-need indications such as glioblastoma multiforme, brain metastases, and head and neck cancers. Founded on research from Duke University and National Jewish Health, the company aims to improve patient outcomes by reducing the toxicity associated with standard-of-care cancer therapies.